Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd > it's not over just a start
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(131)
•••
Comment by gojotv!on Jul 05, 2021 1:08pm
115 Views
Post# 33493239

RE:it's not over just a start

RE:it's not over just a startThe need for Covid testing is evident and ongoing. So will our revenues be. If SZLS revenues merely HOLD for the year, that'll be over $11Million dollars by year-end.
But, it's almost impossible for revenues to merely hold, because of the already-swelling travel boom. Revenues stand to double, or even triple from here. So, anyone with a third-grader's understanding of math can see that the stock price is poised to soar...
So, what could be holding it down?
Are there entities out there that have an interest in holding the price down, discouraging shareholders, and buying up this company on the cheap?
You bet there are.
Everyone knows this is a revenue gold mine.
Big Pharma doesn't want to get away from them.
And neither do I.
Thank-you, Mrs. Baldwin, for being such a great Grade 3 math teacher!
I have a huge advantage over the (extremely few) people selling their SZLS stock today, because you taught me simple multiplication!
GLTA locic-hounds and math fiends!

jp1989 wrote: https://www.lapresse.ca/international/europe/2021-07-03/covid-19-en-russie/cinquieme-jour-consecutif-avec-un-record-de-deces-quotidiens.php


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities